ReviewDrugs2025

Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer.

Eva Valentina Klocker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.